Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Jazz Pharmaceuticals (JAZZ) PT Raised to $208 at BMO Capital
May 8, 2019 7:48 AM EDTBMO Capital analyst Gary Nachman raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $208.00 (from $206.00) while maintaining a Outperform rating.
Nachman commented, "JAZZ delivered strong, high-quality 1Q results with impressive beats on both top and bottom lines while maintaining robust spending... More
Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 51c
May 7, 2019 4:17 PM EDTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $3.67, $0.51 better than the analyst estimate of $3.16. Revenue for the quarter came in at $508.2 million versus the consensus estimate of $465.95 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2019 EPS of $14.30-$15.00, versus the consensus of $14.60.... More
